Shots:

• Zynquista’s CHMP recommendation is based on P-III TANDEM study assessing Zynquista (200mg &400mg) vs insulin in 3-000 patients with T1D mellitus. The study resulted in reduction in blood sugar level and systolic BP @24wks. & improvement in time to maintain targeted blood sugar range
• Dupixent ‘s CHMP recommendation is based on P-III QUEST and VENTURE studies assessing Dupixent vs PBO in 2-888 patients with asthma. The studies resulted in reduction in asthma attacks (exacerbations)- dependency on corticosteroids & improvement in lung function
• Zynquista (200mg &400mg- PO) is an SGLT1 & SGLT2 inhibitor- co-developed by Sanofi and Lexicon with awaited US and EU approval. Dupixent is a mAb- inhibitor of IL-4 & IL-13- co-developed by Sanofi and Regeneron and has received the US FDA & EU approval in asthma & atopic dermatitis respectively

- - Ref: Sanofi | Image: Evaluate Pharma